Understanding sickle cell disease: impact of surveillance and gaps in knowledge | Blood Advances | American Society of Hematology
TO THE EDITOR:
Related Articles
Defining Primary Refractory Large B-cell Lymphoma
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe…
Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim
Key Points. This was a prospective long term follow-up study including 14530 PBSC and 7123 BM volunteer unrelated donors from the NMDP.PBSC and BM donors…
Risk of T-cell Malignancy Following CAR T cells in Children, Adolescents and Young Adults
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon…
CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement – a multicenter experience.
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms
DDX41 germline mutations define the most common genetic syndrome predisposing to myeloid neoplasms (MN). Two papers highlight the genetic landscape and pro
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients
Key Points. Obinutuzumab can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in MCL patients.Obinutuzuma
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
Abstract. The routine use of next-generation sequencing methods has underscored the genetic and clonal heterogeneity of acute myeloid leukemia (AML), subsequent
The approach of HMA plus VEN with or without BMT for all patients with AML
Abstract. Treatment options for acute myeloid leukemia (AML) have expanded over the last 5 years. New regimens are increasing the options for patients who
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Abstract. Intensive chemotherapy in combination with allogeneic hematopoietic cell transplantation and supportive care can induce long-term remissions in a